Literature DB >> 27918641

Evaluation of the Biocompatibility of Polypyrrole Implanted Subdurally in GAERS.

Sebastien H Bauquier1, Karen J McLean2, Jonathan L Jiang2, Ray C Boston2, Alan Lai2, Zhilian Yue3, Simon E Moulton3, Amy J Halliday2, Gordon Wallace3, Mark J Cook2.   

Abstract

This blinded controlled prospective randomized study investigates the biocompatibility of polypyrrole (PPy) polymer that will be used for intracranial triggered release of anti-epileptic drugs (AEDs). Three by three millimeters PPy are implanted subdurally in six adult female genetic absence epilepsy rats from Strasbourg. Each rat has a polymer implanted on one side of the cortex and a sham craniotomy performed on the other side. After a period of seven weeks, rats are euthanized and parallel series of coronal sections are cut throughout the implant site. Four series of 15 sections are histological (hematoxylin and eosin) and immunohistochemically (neuron-specific nuclear protein, glial fibrillary acidic protein, and anti-CD68 antibody) stained and evaluated by three investigators. The results show that implanted PPy mats do not induce obvious inflammation, trauma, gliosis, and neuronal toxicity. Therefore the authors conclude the PPy used offer good histocompatibility with central nervous system cells and that PPy sheets can be used as intracranial, AED delivery implant.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  biocompatibility; cerebral cortex implants; conductive polymers; toxicity

Mesh:

Substances:

Year:  2016        PMID: 27918641     DOI: 10.1002/mabi.201600334

Source DB:  PubMed          Journal:  Macromol Biosci        ISSN: 1616-5187            Impact factor:   4.979


  2 in total

1.  Characterization and antitumor efficacy of poly(L-lactid acid)-based etoposide-loaded implants.

Authors:  Li Gao; Chuanqi Xie; Yuzhi Du; Xiaodong Wang; Erkang Xuan; Xiuxiu Liu; Yang Zhao; Jianjian Xu; Lan Luo
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 2.  Bypassing the Blood-Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies.

Authors:  Manuela Gernert; Malte Feja
Journal:  Pharmaceutics       Date:  2020-11-24       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.